蕭頌華教授 : 心律不正與遙距監察

HKUMed discovers a novel mediator of liver fibrosis and its underlying mechanism that can be a new therapeutic target

HKUMed discovers a novel mediator of liver fibrosis and its underlying mechanism that can be a new therapeutic target

HKUMed reports a simple risk score to identify undiagnosed diabetes and announces the launch of the “HK CRISPS Health Risk Engines” Smartphone App

HKUMed researchers first discovered SARS-CoV-2 infects human neural progenitor cells and brain organoids

HKUMed discovers a novel mediator of cerebral ischaemia injury and its underlying mechanism which can be a new therapeutic target for ischaemic stroke

HKUMed research shows that stroke patients are presenting to hospitals one hour later during COVID-19, potentially jeopardising the patients’ eligibility for treatments and affecting the outcome

HKU Studies the Prevalence of Viral Hepatitis in HK – The First Largest Population Territory-based Study Identifies Areas of Need in Combating Liver Diseases

The research team of Department of Medicine, HKU, and Department of Surgery, North District Hospital (NDH),identify long-term Ketamine abuse damages the biliary system
Damage reversible after quitting Ketamine

HKU team led by Professor David SIU Chung-wah Discovers the Application of Human Induced Pluripotent Stem Cells in Precision Medicine for Hereditary Diseases

HKU and International Collaborative Research Teams Discover Novel Genetic Markers for Blood Lipids and Coronary Artery Disease

HKU Finds that Long-term Use of Proton Pump Inhibitors is Associated with an Increased Risk of Stomach Cancer

HKU Identifies HBV Treatment Reduces Liver Cancer Incidence in Hong Kong Recommends Strengthening Community Outreach to Reduce Number of Liver Cancer Patients

HKU research team led by Prof HF Tse Develops Chimeric Mouse Liver Model Helps Familial Hypercholesterolemia Patients Test Drug Response

HKU Discovers that Traditional Blood Thinner Drug is associated with a Higher Risk of Osteoporotic Fracture compared to Newer Drug

HKU Identifies Homoharringtonine as Effective Treatment for FLT3 Mutant Acute Myeloid Leukaemia for the First Time in the World

HKU Phase 1 Clinical Trials Centre moves forward to its 1st Anniversary

HKU developed the atrial fibrillation (AF) management app and Launch of private doctors AF screening programme

HKU performs the first-in-man restorative treatment – the dual-targeted thoracic spinal cord stimulation for heart failure